2-Administrative-details | IB identification and administrative details | 0 |
2.1.1 | Device identification and naming | 0 |
2.1.2 | Intended purpose and use scope | 0 |
2.1.3 | Intended clinical performance and benefit | 0 |
2.1.4 | Qualification and risk classification | 0 |
2.1.5 | Literature supporting design and use | 0 |
2.1.6.1.1 | Key functional elements description | 0 |
2.1.6.1.2 | Materials overview and contact materials | 0 |
2.1.6.1.3 | Technical specifications and variants | 0 |
2.1.7 | Manufacturing process and quality controls | 0 |
2.1.8 | Previous and similar device generations | 0 |
2.1.9 | Equivalent and similar market devices | 0 |
2.2.1 | Instructions for use in the dossier | 0 |
2.2.2 | Content of device labels | 0 |
2.2.3 | Training needs and plans | 0 |
2.2.4 | Study implant card | 0 |
2.3.1 | General pre-clinical evaluation expectations | 0 |
2.3.2.1 | Design calculations | 0 |
2.3.2.2.1 | Performance testing | 0 |
2.3.2.2.2 | Reliability and durability testing | 0 |
2.3.2.2.3 | Interoperability and compatibility testing | 0 |
2.3.2.2.4 | Usability testing | 0 |
2.3.2.3.1 | Mechanical, electrical safety and EMC tests | 0 |
2.3.2.3.2 | Biocompatibility and biological safety | 0 |
2.3.2.3.3 | Software verification and validation | 0 |
2.3.2.3.4 | Cybersecurity testing evidence | 0 |
2.3.2.3.5 | Cleaning, disinfection and sterilisation validation | 0 |
2.3.2.3.6 | Packaging validation for sterile and non-sterile devices | 0 |
2.3.3 | Animal test summaries | 0 |
2.4 | Existing clinical data overview | 1 |
2.5 | Risk management of the investigational device | 0 |
2.5.1 | Anticipated serious adverse events and device effects | 1 |
2.6.1 | General information on the incorporated substance | 0 |
2.6.2 | Quality documentation for the incorporated substance | 0 |
2.6.2.1 | Quality after incorporation into the device | 0 |
2.6.2.2 | Quality information on the final investigational device | 0 |
2.6.2.3 | Starting materials of biological origin | 0 |
2.6.2.4 | Adventitious agents and TSE safety | 0 |
2.6.2.5 | Substances derived from human plasma | 0 |
2.6.2.6 | Substances of animal origin | 0 |
2.7 | Fulfilment of safety and performance requirements | 0 |
2.8 | Diagnostic tests and clinical procedures | 0 |
APP-A | Checklist against MDR Annex XV, Chapter II, Section 2 | 0 |
CL1 | Purpose and scope of the guidance | 0 |
CL2 | IB content principles and stand-alone reading | 0 |
CL2.1 | Device information heading | 0 |
CL2.1.6 | General device description heading | 0 |
CL2.1.6.1 | Design description heading | 0 |
CL2.2 | Labels and instructions for use scope | 0 |
CL2.3 | Pre-clinical evaluation scope | 0 |
CL2.3.2 | Specific pre-clinical test types | 0 |
CL2.3.2.2 | Bench tests for any device | 0 |
CL2.3.2.3 | Vertical bench testing overview | 0 |
CL2.6 | Devices with medicinal substance or biological constituents | 0 |